Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab

Enfortumab vedotin with pembrolizumab (EV + pembro) has transformed first-line treatment of advanced urothelial carcinoma (aUC). No prospective data are available evaluating outcomes of different therapies following progression on EV + pembro. Patients who received first-line EV + pembro and had sec...

Полное описание

Библиографические подробности

Главные авторы:	Georges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, Varun Nandakumar, Antonio Cigliola, Valentina Tateo, Edwin Lin, Micah Ostrowski, Nicolas Sayegh, Ethan Murdock, Vinay Mathew Thomas, Sumati Gupta, Neeraj Agarwal, Umang Swami
Формат:	Artigo
Язык:	Inglês
Опубликовано:	SAGE Publishing 2026-01-01
Серии:	Bladder Cancer
Online-ссылка:	https://doi.org/10.1177/23523735261437911
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!